Pharmaceutical Packaging Labels: FDA Rules for Rx and OTC Drugs

FDA requirements for pharmaceutical packaging labels are set out mainly in 21 CFR Part 201 and cover what must appear on a drug’s container and carton, how it must be formatted, and how prominently it must be displayed. The rules split into two tracks: prescription drugs follow a structured prescribing-information format aimed at clinicians, while over-the-counter products carry a standardized Drug Facts panel written for consumers. Both must be accurate, legible, and complete, or the drug is legally misbranded.

What “Labeling” Covers and Why It Matters

Federal law defines labeling broadly. It includes every written, printed, or graphic piece of material on or accompanying a drug as it moves through commerce, from the sticker on a bottle to the paper insert folded inside the box. Under the Federal Food, Drug, and Cosmetic Act, a drug is misbranded whenever its labeling is false or misleading in any particular, or when it omits required information such as the manufacturer’s name, the quantity of contents, or the drug’s established name.¹ Introducing a misbranded drug into interstate commerce, receiving one, or holding it for sale after shipment are all prohibited acts.²

That framing shapes everything that follows. The specific formatting rules exist because the misbranding statute makes noncompliance a federal offense, not a paperwork issue.

Prescription Drug Label Requirements

Prescription labeling follows 21 CFR 201.56 and 201.57. Every label opens with a “Highlights of Prescribing Information” section giving providers a quick overview of the most critical data. Within Highlights, the label must show the drug’s proprietary (brand) name, its established (generic) name, the dosage form, and the route of administration. Controlled substances also display the appropriate schedule symbol.³

Below Highlights, a table of contents guides clinicians into the full prescribing information, which follows a mandatory numbered sequence: indications and usage, dosage and administration, dosage forms and strengths, contraindications, warnings and precautions, adverse reactions, drug interactions, and use in specific populations, among other sections. The predictable order lets a prescriber find contraindications or interactions before writing a script.

Boxed Warnings

When risks are serious enough to warrant special attention, FDA can require a boxed warning. It is the most prominent safety alert on a prescription label: a bolded, bordered summary headed by the word “WARNING” in uppercase, capped at 20 lines, directing the reader to fuller information elsewhere in the labeling.³

Pregnancy and Lactation Information

Since 2015, the Pregnancy and Lactation Labeling Rule has replaced the older A/B/C/D/X letter categories with narrative subsections. Subsection 8.1 (Pregnancy) includes a risk summary, clinical considerations, supporting data, and registry information where an exposure registry exists. Subsection 8.2 (Lactation) addresses presence in breast milk and effects on a nursing infant. Subsection 8.3 covers pregnancy testing, contraception, and fertility effects in females and males of reproductive potential.⁴

Medication Guides

Some drugs are subject to a Risk Evaluation and Mitigation Strategy. When a REMS includes a Medication Guide, the pharmacist must dispense that guide to the patient with every fill. Medication Guides are written in plain language for patients rather than clinicians, covering the drug’s most serious risks and what to watch for.⁵

OTC Drug Facts Panel

Over-the-counter products carry a Drug Facts panel governed by 21 CFR 201.66. It must appear on the outer retail package, or on the immediate container if there is no outer packaging, in a standardized layout that looks the same across every OTC product on the shelf.⁶

The panel runs in a fixed sequence:

Active ingredients, with amount per dose and purpose of each.
Uses, meaning the specific symptoms or conditions the product treats.
Warnings, covering side effects, drug interactions, and situations where the product should not be used or a doctor should be consulted first.
Directions, including dose amounts, frequency, and age-specific instructions.
Other information, including storage conditions.
Inactive ingredients, listed alphabetically.

The alphabetical inactive-ingredient list is what someone with a dye or preservative allergy checks in the aisle. The fixed order also keeps warnings high on the panel rather than buried under marketing copy.⁶

Expiration Dates

Every drug product must carry an expiration date backed by stability testing. Under 21 CFR 211.137, the date reflects the point through which the manufacturer’s testing confirms the product still meets standards for identity, strength, quality, and purity, and it must correspond to the storage conditions printed on the label. A product stored at controlled room temperature will have a different shelf life than one requiring refrigeration.⁷

Products that must be reconstituted at the pharmacy before dispensing need expiration information for both the unmixed and reconstituted forms, since shelf life drops sharply once liquid is added. Where the expiration date sits on the package is governed by 21 CFR 201.17.

Tamper-Evident Packaging

Most OTC drugs sold at retail must come in tamper-evident packaging under 21 CFR 211.132. The package needs at least one indicator or barrier that shows visible evidence if it has been breached. The design must be distinctive enough, whether by shape, logo, pattern, or trademark, that it cannot easily be duplicated with common materials. Dermatological products, dentifrices, insulin, and lozenges are exempt.⁸

The labeling side of this rule matters as much as the physical seal. Each covered retail package must carry a statement identifying the specific tamper-evident feature used, and that statement must be placed so it remains intact even if the tamper-evident feature itself is breached or missing. An OTC product missing either the packaging or the required statement is considered adulterated, misbranded, or both.⁸

Small Containers

Blister cells, small vials, and ampules often cannot fit the full label. Under 21 CFR 201.10(i), the immediate container must still display, at a minimum:

The name and address of the manufacturer, packer, or distributor.
The established name of the drug.
The net quantity of contents.
The lot or control number for traceability.
The expiration date.

The outer retail package must still carry the complete labeling. This two-tier approach keeps every individual dose identifiable and traceable while ensuring full safety information reaches the consumer on the carton.⁹

Legibility, Prominence, and Language

A label that technically contains the right information but prints it too small to read fails the legal standard. Under 21 CFR 201.15, all required statements must be displayed prominently enough that an ordinary person can read and understand them under normal conditions of purchase and use. A label can miss this mark by burying required text on a hidden panel, using illegibly small type, choosing poor contrast, or crowding statements with decorative designs.¹⁰

For Drug Facts panels, minimum type sizes are specified. Body text and subheadings must be at least 6-point. Section headings must be at least 8-point, or two point sizes larger than the body text, whichever is bigger. When the Drug Facts panel and other required information take up more than 60 percent of the available label surface, slightly smaller minimums apply (7-point for headings, for example), but the 6-point floor for body text holds.⁶

Required label text must appear in English. The statutory exception covers products distributed solely in Puerto Rico or a U.S. territory where the predominant language is not English; in those cases the predominant local language may substitute.¹⁰

Barcodes and Serialization

Beyond the patient-facing label, prescription drug packaging carries machine-readable data required by the Drug Supply Chain Security Act. Each saleable prescription drug unit must bear a product identifier encoded in a two-dimensional barcode, containing four elements: the National Drug Code, a unique serial number of up to 20 characters, the lot number, and the expiration date.¹¹ The serial number turns every package into a traceable unit, so a suspect or illegitimate product can be traced back to its origin.

What Happens When a Label Falls Short

Enforcement can escalate quickly. FDA can seize misbranded products under 21 U.S.C. § 334 or seek a federal injunction under 21 U.S.C. § 332 to stop distribution. On the criminal side, a first offense carries up to one year in prison and a $1,000 statutory fine. If the violation involves intent to defraud or follows a prior conviction, penalties rise to three years and $10,000. The most serious violations, involving knowing adulteration that risks serious harm or death, reach up to 20 years and $1,000,000.¹² Civil money penalties add another layer, with amounts periodically adjusted for inflation.

Reporting a Problem With a Drug Label

If you run into a drug with confusing, incomplete, or incorrect labeling, FDA accepts reports through MedWatch. Healthcare professionals file on Form 3500 and consumers use Form 3500B; both can be submitted online. These reports are how the agency identifies real-world problems like confusing dosing instructions or look-alike packaging that leads to medication mix-ups.¹³

1
Office of the Law Revision Counsel. 21 USC 352 – Misbranded Drugs and Devices
2
Office of the Law Revision Counsel. 21 USC 331 – Prohibited Acts
3
eCFR. 21 CFR 201.57 – Specific Requirements on Content and Format of Labeling for Human Prescription Drug and Biological Products
4
Food and Drug Administration. Pregnancy and Lactation Labeling Resources
5
Food and Drug Administration. Medication Guides – Distribution Requirements for Health Care Professionals
6
eCFR. 21 CFR 201.66 – Format and Content Requirements for Over-the-Counter Drug Product Labeling
7
eCFR. 21 CFR 211.137 – Expiration Dating
8
eCFR. 21 CFR 211.132 – Tamper-Evident Packaging Requirements for Over-the-Counter Human Drug Products
9
eCFR. 21 CFR Part 201 – Labeling
10
eCFR. 21 CFR 201.15 – Drugs; Prominence of Required Label Statements
11
Food and Drug Administration. Enhanced Drug Distribution Security at the Package Level Under the DSCSA
12
Office of the Law Revision Counsel. 21 USC 333 – Penalties
13
Food and Drug Administration. MedWatch Forms for FDA Safety Reporting